Literature DB >> 25967460

Gut microbes, immunity, and spondyloarthritis.

Matthew L Stoll1.   

Abstract

The last decade has witnessed an explosion of studies evaluating the impact of the human microbiota on a variety of disease states. The microbiota can impact diseases in multiple ways, including through abnormalities in the diversity and contents of the microbiota, as well as by acting as targets of immunologic dysregulation. Herein, evidence that the microbiota in spondyloarthritis is both altered and abnormally targeted by the immune system will be presented.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammatory bowel disease; Microbiome; Microbiota; Spondyloarthritis

Mesh:

Year:  2015        PMID: 25967460     DOI: 10.1016/j.clim.2015.05.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  Self or non-self? The multifaceted role of the microbiota in immune-mediated diseases.

Authors:  Martin A Kriegel
Journal:  Clin Immunol       Date:  2015-05-21       Impact factor: 3.969

Review 2.  Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Authors:  Ananta Paine; Christopher T Ritchlin
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

3.  Spondyloarthropathies: Ruminococcus on the horizon in arthritic disease.

Authors:  Lars Vereecke; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2017-08-17       Impact factor: 20.543

4.  Perturbed Mucosal Immunity and Dysbiosis Accompany Clinical Disease in a Rat Model of Spondyloarthritis.

Authors:  Mark J Asquith; Patrick Stauffer; Sean Davin; Claire Mitchell; Phoebe Lin; James T Rosenbaum
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

Review 5.  The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target?

Authors:  Matthew L Stoll; Randy Q Cron
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

6.  Fecal metabolomics in pediatric spondyloarthritis implicate decreased metabolic diversity and altered tryptophan metabolism as pathogenic factors.

Authors:  M L Stoll; R Kumar; E J Lefkowitz; R Q Cron; C D Morrow; S Barnes
Journal:  Genes Immun       Date:  2016-10-27       Impact factor: 2.676

Review 7.  A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Lianjun Yang; Liping Wang; Xin Wang; Cory J Xian; Hai Lu
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

8.  Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial.

Authors:  Maja Skov Kragsnaes; Jens Kjeldsen; Hans Christian Horn; Heidi Lausten Munk; Finn Moeller Pedersen; Hanne Marie Holt; Jens Kristian Pedersen; Dorte Kinggaard Holm; Henning Glerup; Vibeke Andersen; Ulrich Fredberg; Karsten Kristiansen; Robin Christensen; Torkell Ellingsen
Journal:  BMJ Open       Date:  2018-04-27       Impact factor: 2.692

Review 9.  Gut microbiota-host interactions and juvenile idiopathic arthritis.

Authors:  Miika Arvonen; Lillemor Berntson; Tytti Pokka; Tuomo J Karttunen; Paula Vähäsalo; Matthew L Stoll
Journal:  Pediatr Rheumatol Online J       Date:  2016-07-22       Impact factor: 3.054

10.  Age and fecal microbial strain-specific differences in patients with spondyloarthritis.

Authors:  Matthew L Stoll; Pamela F Weiss; Jennifer E Weiss; Peter A Nigrovic; Barbara S Edelheit; S Lou Bridges; Maria I Danila; Charles H Spencer; Marilynn G Punaro; Kenneth Schikler; Andreas Reiff; Ranjit Kumar; Randy Q Cron; Casey D Morrow; Elliot J Lefkowitz
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.